NASDAQ:QLGN Qualigen Therapeutics (QLGN) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free QLGN Stock Alerts $0.29 -0.01 (-3.33%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.2950-Day Range$0.30▼$0.5852-Week Range$0.27▼$1.26Volume72,159 shsAverage Volume59,800 shsMarket Capitalization$1.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Qualigen Therapeutics alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Qualigen Therapeutics Stock (NASDAQ:QLGN)Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Read More QLGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QLGN Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comQualigen Announced An Agreement With Marizyme To Commercialize DuraGraftApril 16, 2024 | finance.yahoo.comMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™May 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 12, 2024 | uk.investing.comQualigen presents preclinical novel cancer inhibitors at AACR 2024April 10, 2024 | globenewswire.comQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingApril 9, 2024 | globenewswire.comQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingFebruary 22, 2024 | morningstar.comQualigen Therapeutics Inc Ordinary Shares QLGNFebruary 7, 2024 | uk.investing.comQualigen Therapeutics Inc (QLGN)May 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.November 27, 2023 | finance.yahoo.comQLGN: Dosing Begins in Phase 1 Trial of QN-302…November 14, 2023 | finance.yahoo.comQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023November 7, 2023 | finance.yahoo.comQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsOctober 23, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerSeptember 27, 2023 | finance.yahoo.comQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023September 2, 2023 | ca.finance.yahoo.comQualigen Therapeutics Inc (7R9.DU)August 30, 2023 | finance.yahoo.comQLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…August 17, 2023 | finance.yahoo.comQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsAugust 15, 2023 | msn.comQualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62MAugust 15, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023August 1, 2023 | finance.yahoo.comQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsJuly 24, 2023 | finance.yahoo.comQualigen Therapeutics Divests FastPack® Diagnostics BusinessJune 14, 2023 | finance.yahoo.comQLGN: Data for Pan-RAS Platform Presented at ASCO…June 6, 2023 | technews.tmcnet.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 5, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 18, 2023 | seekingalpha.comQualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61MMay 16, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023May 12, 2023 | finance.yahoo.comQLGN: IND for QN-302 to be Submitted in Mid-2023…See More Headlines Receive QLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2023Today5/02/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QLGN CUSIPN/A CIK1460702 Webwww.qualigeninc.com Phone(760) 918-9165FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,420,000.00 Net MarginsN/A Pretax Margin-1,235.43% Return on Equity-841.99% Return on Assets-137.02% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$4.98 million Price / Sales0.37 Cash FlowN/A Price / Cash FlowN/A Book Value($0.41) per share Price / Book-0.71Miscellaneous Outstanding Shares6,310,000Free Float5,941,000Market Cap$1.83 million OptionableNot Optionable Beta-0.73 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael S. Poirier (Age 68)President, COO, CEO & Chairman Comp: $632.7kMr. Christopher L. Lotz (Age 59)VP of Finance, CFO & Corporate Secretary Comp: $578.55kKey CompetitorsPainReformNASDAQ:PRFXBio-PathNASDAQ:BPTHBiodexa PharmaceuticalsNASDAQ:BDRX180 Life SciencesNASDAQ:ATNFGalmed PharmaceuticalsNASDAQ:GLMDView All Competitors QLGN Stock Analysis - Frequently Asked Questions How have QLGN shares performed in 2024? Qualigen Therapeutics' stock was trading at $0.55 on January 1st, 2024. Since then, QLGN stock has decreased by 47.2% and is now trading at $0.2903. View the best growth stocks for 2024 here. Are investors shorting Qualigen Therapeutics? Qualigen Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 49,400 shares, a decrease of 38.2% from the March 31st total of 79,900 shares. Based on an average daily volume of 65,000 shares, the short-interest ratio is presently 0.8 days. Currently, 0.9% of the company's stock are sold short. View Qualigen Therapeutics' Short Interest. When is Qualigen Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our QLGN earnings forecast. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its quarterly earnings results on Tuesday, August, 15th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.17. The company earned $1.63 million during the quarter, compared to analysts' expectations of $1.60 million. What other stocks do shareholders of Qualigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Platforms (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH). How do I buy shares of Qualigen Therapeutics? Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QLGN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithNew Trump BombshellThe Freeport SocietyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
